Clinical navigation | Global evidence for practicing physicians - hover any section to explore
Current guidelines
2025 AHA/ACC Hypertension Guideline
Jones DW et al. | Circulation/JACC | Aug 2025
2023 ESH Hypertension Guidelines
European Society of Hypertension | J Hypertens 2023
2024 ESC Elevated BP & Hypertension
European Society of Cardiology | Eur Heart J 2024
WHO Global Report on Hypertension 2025
Second WHO global report | Action agenda
AHA/ACC vs ESH vs ESC - global comparison
Thresholds, targets & drug choice
Hypertension - specialty journals
Hypertension (AHA)
Official AHA journal | IF 8.3 | Monthly
Journal of Hypertension (ESH)
Official ESH journal | Wolters Kluwer
American Journal of Hypertension
Oxford University Press | IF 3.2
Cardiovascular - high-impact global
New England Journal of Medicine
World's highest-impact medical journal
JACC
J Am Coll Cardiology | IF 21.7
The Lancet
Global health | High-impact trials
European Heart Journal
ESC flagship | Oxford | IF 35.9
Upcoming 2026 - global hypertension & cardiovascular
Jul 13-16, 2026
AHA Hypertension Scientific Sessions
Boston, MA, USA
Upcoming
Aug 28-31, 2026
ESC Congress 2026
Munich, Germany
Upcoming
2026 | TBC
ISH-ECS Scientific Meeting
Dubai, UAE
Upcoming
Nov 2026 | TBC
AHA Scientific Sessions 2026
Chicago, IL, USA
Upcoming
Mar 28-30, 2026
ACC Scientific Sessions 2026
New Orleans, LA
May 9-12, 2026
ESC Heart Failure Congress 2026
Barcelona, Spain
Breaking trials - 2025-2026
BaxHTN - baxdrostat Phase III (NEJM 2025)
-9.7 mmHg SBP | FDA Priority Review Q2 2026
ADVANCE-HTN - lorundrostat Phase 2b (ACC 2025)
Aldosterone synthase inhibition | 24-hr BP
SPYRAL HTN & RADIANCE - RDN trials
Class IIb evidence | Resistant HTN
Global & LMIC research
Global HTN trends 2000-2020 (JACC 2026)
83% of uncontrolled HTN now in LMICs
WHO HEARTS & ACHIEVE - LMIC programs
40+ countries | BP control scale-up
Clinical Q&A
Submit a clinical question
Expert-reviewed | Citable responses
Top questions on 2025 guideline
Most-viewed | Updated weekly
Global practice - LMIC Q&A
Resource-limited settings | WHO HEARTS
PREVENT calculator - clinical FAQs
Application, interpretation, edge cases
CME credit & accreditation FAQs
AMA PRA Cat. 1 | MOC | ECMEC
WHO 2025: 1.4 billion people worldwide live with hypertension - fewer than 1 in 5 adequately controlled. 83% of uncontrolled cases now in LMICs. | 2025 AHA/ACC Guideline live - first update since 2017.
WHO report
Global physician continuing education
The world's hypertension burden demands updated clinical knowledge
Evidence-based CME drawing on worldwide data, the 2025 AHA/ACC guideline, WHO global reports, and emerging therapies - for physicians practicing in any setting.
HTN prevalence by region
North America~47%
Sub-Saharan Africa~46%
Latin America & Caribbean~38%
South Asia~28%
East Asia & Pacific~25%
WHO GHO 2025 | Adults 30-79 yrs
1.4B
Adults worldwide with hypertension | WHO 2025
<1 in 5
Adequately controlled globally | Lancet 2025
83%
Of uncontrolled HTN now in LMICs | JACC 2026
10.8M
Annual deaths attributable to high BP | GBD
2025
AHA/ACC guideline - first update since 2017
Global hypertension burden
Interactive Map
Hover any country to explore the latest regional hypertension statistics | WHO GHO 2025 | JACC 2026 | Lancet 2025
Hover over any country on the map to see that region's latest hypertension statistics
BP control rate classification | WHO GHO 2025
Control rate: Critical (<15%) Low (15-30%) Moderate (30-45%) Higher (>45%) No data
2025 AHA/ACC guideline - key updates
AHA/ACC | August 2025
Core changes reshaping hypertension management
Jones DW et al. J Am Coll Cardiol / Circulation / Hypertension. 2025
PREVENT calculator replaces pooled cohort equations
Integrates cardiovascular, renal, and metabolic health - eGFR, BMI, statin use, social determinants. Race no longer a determinant, addressing global equity concerns.
New
Risk-based medication initiation thresholds
Pharmacotherapy at BP >=130/80 for CVD, diabetes, CKD, or 10-year CVD risk >=7.5% via PREVENT. Without these factors: threshold remains >=140/90.
Revised
Renal denervation - Class IIb adjunctive option
RDN endorsed for select resistant hypertension patients. Requires multidisciplinary evaluation and shared decision-making. Follows ESC/ESH global endorsement.
New
Primary aldosteronism screening expanded
Screening for all stage 2 and resistant HTN patients. Significantly underdiagnosed secondary cause worldwide, particularly in LMICs.
Expanded
Expanded special population guidance
Revised guidance for CKD, diabetes, pregnancy, intracerebral hemorrhage, and hypertensive emergencies - applicable across global care settings.
Expanded
Drug pipeline - resistant & uncontrolled hypertension
Baxdrostat
Aldosterone synthase inhibitor | AstraZeneca | Global Phase III
FDA Priority Review
Systolic reduction
-9.7 mmHg
vs. placebo delta
~-6 mmHg
International Phase III BaxHTN trial met all endpoints in resistant/uncontrolled HTN. PDUFA Q2 2026. Presented ESC Congress 2025; simultaneously published NEJM.
Flack JM et al. N Engl J Med. 2025;393:1363-1374 | Full trial review
Lorundrostat
Aldosterone synthase inhibitor | Mineralys Therapeutics
Phase III
24-hr BP lowering
Significant
ADVANCE-HTN Phase 2b (ACC 2025): effective 24-hr BP reduction in treatment-resistant HTN, low hyperkalemia incidence. NDA filing Q4 2025-Q1 2026.
ADVANCE-HTN | ACC Scientific Sessions, March 2025 | Read analysis
CME modules
2025 guideline: what changed
Aug 2025 | 2.0 AMA PRA Cat. 1
Global HTN burden & equity gaps
2025 | 1.5 AMA PRA Cat. 1
Applying PREVENT in practice
Sep 2025 | 1.0 AMA PRA Cat. 1
Renal denervation: patient selection
Oct 2025 | 1.5 AMA PRA Cat. 1
Resistant HTN & aldosteronism
Nov 2025 | 2.0 AMA PRA Cat. 1
Latest from the journals
NEJM | Aug 2025
Efficacy and safety of baxdrostat in resistant hypertension
Flack JM et al. | NEJM 2025;393:1363
Lancet | Nov 2025
WHO global report on hypertension 2025 - urgent action agenda
Lancet 2025 | 1.4B worldwide, <1 in 5 controlled
JACC | Mar 2026
Global HTN trends 2000-2020: 83% uncontrolled in LMICs
O'Connell SS et al. | JACC 2026;87:2338
Lancet | Feb 2026
New drug therapies for hypertension - emerging classes globally
Lancet 2026;407 | Feb 10
WHO 80x80x80 target
By 2030, the World Hypertension League targets: 80% diagnosed, 80% treated, 80% with controlled BP.
Current global control rate
19.7% - substantial gap to 2030 target
Global Hypertension Updates & CME
Worldwide evidence | Physician continuing education
For licensed physicians only | Not for patient use | International editorial board | Data: WHO, AHA, ESC, JACC, Lancet
AccreditationEditorial boardReferencesPrivacy
© 2026 Global Hypertension Updates & CME. All original text, design, and illustrations on this page are the property of their respective author(s) and may not be reproduced without permission.
This page contains original editorial summaries of publicly available clinical guidelines and peer-reviewed research (see References). No text, tables, or figures have been copied from the cited sources; all statistics are paraphrased and independently sourced or aggregated. Guideline names (AHA/ACC, ESC/ESH, WHO) and journal names (NEJM, JACC, Lancet, Circulation, Hypertension) are used solely to identify and attribute the underlying sources and are the trademarks of their respective owners; no endorsement of this page by those organizations is implied. Drug and company names (e.g., Baxdrostat®/AstraZeneca, Lorundrostat/Mineralys Therapeutics) are trademarks of their respective owners and are used for identification purposes only, under nominative fair use.
This content is intended for licensed healthcare professionals for educational purposes only and does not constitute medical advice. It is not a substitute for reading full original source publications, which remain under the copyright of their respective publishers.